<DOC>
	<DOCNO>NCT02510053</DOCNO>
	<brief_summary>To investigate pharmacokinetics ( PK ) pharmacodynamics ( PD ) Caspofungin ICU patient receive load dose 70mg follow 50mg ( 35mg Child-Pugh score 7-9 ) , 40 patient recruit . Blood sampling PK analysis collect day 4 study . Caspofungin plasma concentration measure use solid phase extraction reverse phase high-performance liquid chromatography . Safety analyse take daily treatment Caspofungin . Tests drug tolerance fungi efficacy assessment ( clinical mycological response ) take every 3 day clinical mycological test .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Caspofungin ( Cancidas Â® ) Drug Tolerance Fungi Patients With Invasive Fungal Infection Intensive Care Unit</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patient admit ICU APACHEII score 15 Subject 18 year old old day first dose Subject evidence proven probable IFI define modify criterion European Organization Research Treatment Cancer ( EORTC ) patient know hypersensitive caspofungin patient 's ChildPugh score 9 patient prone discontinue treatment result lack cost patient guardian refuse sign inform consent form patient concurrently receive efavirenz , nevirapine , rifampin , systemic dexamethasone , phenytoin , carbamazepine , phenobarbital , cyclosporine agent influence PK parameter caspofungin patient treat caspofungin within 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>